A new national television campaign for treating depression, launched yesterday by Neuronetics, reflects their unparalleled dedication to promoting the science of Transcranial Magnetic Stimulation (TMS) and its benefits to patients receiving NeuroStar rTMS treatment around the globe. In advance of May?? Mental Health Awareness Month, messages like this are paramount in the effort to change the tone of the discussion about mental health issues.
Major Depressive Disorder (MDD):
While major depressive disorder can develop at any age, the median age at onset is 32.5 years old.
- MDD affects more than 16.1 million American adults
- MDD is the leading cause of disability in the U.S. for ages 15 to 44.3. or about 6.7% of the U.S. population age 18 and older in a given year.
- MDD is more prevalent in women than in men.
- MMD has a $210 billion effect on the U.S. economy.
Robert Sammons, M.D., Ph.D. and Co-Founder Christopher Blackburn of TMS Solutions thank Neuronetics for continuing their commitment to publicly educate about TMS Therapy. As TMS providers since 2013, we have faced the challenge of educating the public about this life-changing technology. We have fought insurance companies all the way to state Health Departments??nd won. These efforts have created broader coverage for TMS and affected hundreds of thousands of lives. Through our partnerships with key organizations, like the Veterans??Administration and participation in clinical trials with top-tier medical schools and health care providers like Mayo Clinic, Harvard University, and Sheppard-Pratt, we have honed our skills as a provider.
“”We currently boast a remission rate of 47% and a response of 80% in all patient populations we have treated.”” Chris Blackburn, Co-Founder/CEO
It is through the exceptional support from NeuroStar that providers such as ourselves are able to make a difference in the lives of so many people afflicted with depression.
If you suffer from depression, learn more about how TMS Therapy is changing lives — click the button below.